TMCnet News
Prenosis and Winners of the Chicago Innovation Awards Ring the Opening Nasdaq BellPrenosis recognized for its AI-directed precision therapeutics platform for acute illness CHICAGO, Aug. 31, 2026 /PRNewswire/ -- Prenosis®, a biology-based technology company delivering precision therapeutics, will join fellow winners of the Chicago Innovation Awards, the Chicago region's foremost annual celebration of innovation, in New York City on Monday, August 31st to ring the Opening Nasdaq Bell. The event emphasizes the breadth of innovation in the Chicago region and shines a spotlight on the organizations that make up its vibrant economy.
"Chicago Innovation Award winners cut across all industries and represent the best in new product and service development from large companies, startups and non-profits," said Luke Tanen, President and CEO of Chicago Innovation. "Their winning innovations are solving a range of unmet needs in the marketplace, and we're proud to celebrate their successes on a global stage by ringing the Nasdaq Bell." Joining Prenosis will be other winners of the 2025 Chicago Innovation Awards. The full list of 2025 winners includes Abbott, Aegis Foods, Chamberlain Group, CharCharms, ClostraBio, CloudNuro, Cultivate Collective, Cylinder Health, Ganance, GigaStar, Ignite, Latinos Progresando & Greater Auburn Gresham Development Corporation, Prenosis, (P)Rind, Medill School of Journalism at Northwestern University, Sphera, Sunshine Enterprises, Trajektory, Urban Growers Collective, Xchange Chicago and Zerno. Prenosis is building an I-directed precision therapeutics platform for acute illness, the infrastructure through which precision therapeutics are identified, clinically validated, and delivered. The company's winning innovation, Sepsis ImmunoScore®, built on Prenosis' Immunix® platform, is the first-ever FDA-authorized AI diagnostic for sepsis. The solution integrates biological and clinical data to generate real-time insights into a patient's immune response, enabling clinicians to detect sepsis, or the progression to sepsis within 24 hours. "Being named a Chicago Innovation Award winner is a powerful recognition of what our team has built," said Bobby Reddy, Jr., PhD, CEO and Co-founder of Prenosis. "For decades, therapies that could save lives in sepsis, pneumonia and other acute conditions have failed in clinical trials due to the heterogeneity of the patient. Now, AI is uniquely suited to solve that problem. It allows us to finally uncover how each patient will respond to a given therapy, at the scale and speed clinical trials require. Using our AI-directed methodology, we aim to tailor treatment based on each patient's underlying biology, and Sepsis ImmunoScore® was our first proof point. We're honored to have Chicago Innovation recognize the platform we're building, one that will bring precision therapeutics to the millions of patients treated for acute conditions every year." About Prenosis About Chicago Innovation and the Chicago Innovation Awards
SOURCE Prenosis
|
